TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31049072

Group type: EXPERIMENTAL
Intervention: TF20 (HIFT program)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 13
Study: 31049365

Group type: EXPERIMENTAL
Intervention: UC plus peer mentors (n = 54)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: UC plus cash incentives (n = 54)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (UC) (n = 36)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups received 12 weeks of ledipasvir/sofosbuvir (LDV/SOF)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144
Study: 31049557

Group type: EXPERIMENTAL
Intervention: Combined non-invasive/invasive risk stratification approach with programmed ventricular stimulation (PVS) and implantable cardioverter-defibrillator (ICD) offered to inducible patients.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Patients with at least one positive non-invasive risk factor (NIRF) referred for PVS.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Algorithm for risk stratification.
Number of subjects: 575

Group type: COMPARATOR
Intervention: Patients without NIRFs or with NIRFs but negative PVS.
Number of subjects: 575
Study: 31049754

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) for monitoring regional cerebral oxygenation (rSO2)
Number of subjects: 0
Study: 31049885

Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution (5, 10, or 20 mg/kg single dose on day 1; 10 mg/kg, 20 mg/kg, or 40 mg/kg total daily dose for days 4-10)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution (40 mg/kg/day) with clobazam
Number of subjects: 61
Study: 31050224

Group type: EXPERIMENTAL
Intervention: Initial-shockable rhythms
Number of subjects: 4219

Group type: COMPARATOR
Intervention: Converted-shockable rhythms
Number of subjects: 4219

Group type: COMPARATOR
Intervention: Never-shockable rhythms
Number of subjects: 4219

Group type: EXPERIMENTAL
Intervention: TOR criteria including unwitnessed events, no pre-hospital return of spontaneous circulation, and asystole in the emergency department
Number of subjects: 4219
Study: 31050659

Group type: EXPERIMENTAL
Intervention: UCPPS
Number of subjects: 153

Group type: COMPARATOR
Intervention: Mixed pain group
Number of subjects: 153

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 153
Study: 31050691

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 452

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 452
Study: 31050868

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 0
Study: 31050919

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 162
Study: 31051496

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acid supplementation
Number of subjects: 47
Study: 31051503

Group type: EXPERIMENTAL
Intervention: Healthy foods (raw fruits, fish)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Unhealthy foods (fried products, sodas, fatty sweet products, processed meats, ready-cooked meals, desserts)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Fruits, fried products, ready-cooked meals, cheese
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 862
Study: 31053093

Group type: EXPERIMENTAL
Intervention: CDI-DaySyms™ questionnaire
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Diarrhea Symptoms domain
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Abdominal Symptoms domain
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Systemic/Other Symptoms domain
Number of subjects: 168
Study: 31053102

Group type: EXPERIMENTAL
Intervention: Maternal microbiota transfer to neonates during the first 1000 days of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary information and environmental factors (gestational age, mode of delivery, maternal/infant diet, exposure to antibiotics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific qPCR and 16S rRNA gene sequencing, SCFAs profile
Number of subjects: 0
Study: 31053156

Group type: EXPERIMENTAL
Intervention: Cumulative Analogue Joint Involvement Scale (CAJIS)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: FOP-Physical Function Questionnaire (FOP-PFQ)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HO volume measured by low-dose whole body CT
Number of subjects: 114
Study: 31053174

Group type: EXPERIMENTAL
Intervention: Avelumab (PD-L1 blockade)
Number of subjects: 12
Study: 31053210

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Snoring question
Number of subjects: 99
Study: 31053538

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 33
Study: 31053601

Group type: EXPERIMENTAL
Intervention: Low baseline peripheral blood NK-cell count (NKCC)
Number of subjects: 0
Study: 31053957

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction (HFpEF) patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patients without HFpEF (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Compensated HFpEF patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RA-RV coupling in HFpEF patients
Number of subjects: 36
Study: 31054013

Group type: EXPERIMENTAL
Intervention: IVC filter
Number of subjects: 1065

Group type: COMPARATOR
Intervention: No IVC filter
Number of subjects: 1065
Study: 31054035

Group type: EXPERIMENTAL
Intervention: MS Performance Test (MSPT)
Number of subjects: 1000
Study: 31054118

Group type: EXPERIMENTAL
Intervention: Risankizumab (0.01-5 mg/kg IV, 200-1200 mg IV, 0.25-1 mg/kg SC, 18-300 mg SC)
Number of subjects: 1899
Study: 31055187

Group type: EXPERIMENTAL
Intervention: Elective surgery
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Acute surgery
Number of subjects: 5063
Study: 31055613

Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cell therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: replacement and anticoagulant therapy
Number of subjects: 53
Study: 31055977

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31056078

Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction
Number of subjects: 1
Study: 31056369

Group type: EXPERIMENTAL
Intervention: Food-insecure households
Number of subjects: 218

Group type: COMPARATOR
Intervention: Food-secure households
Number of subjects: 218
Study: 31056411

Group type: EXPERIMENTAL
Intervention: Current guideline-recommended ECG criteria for STEMI
Number of subjects: 2486
Study: 31057004

Group type: EXPERIMENTAL
Intervention: Good adherence (taking medications ≥90% of the time as prescribed)
Number of subjects: 4001

Group type: COMPARATOR
Intervention: No medications prescribed during follow-up
Number of subjects: 4001

Group type: COMPARATOR
Intervention: Taking ≥1 medications
Number of subjects: 4001
Study: 31057439

Group type: COMPARATOR
Intervention: Emotion reappraisal task
Number of subjects: 39

Group type: COMPARATOR
Intervention: Baseline craving levels
Number of subjects: 39
Study: 31057616

Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) using indocyanine green (ICG) for locating upper extremity lymphatics.
Number of subjects: 44
Study: 31057686

Group type: EXPERIMENTAL
Intervention: Surveillance MRI
Number of subjects: 1
Study: 31057807

Group type: EXPERIMENTAL
Intervention: Carepartner and Constraint-Induced Therapy (CARE-CITE) with structured carepartner involvement during 30-h CIMT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT) without structured carepartner involvement
Number of subjects: 48
Study: 31057971

Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 47
Study: 31058707

Group type: EXPERIMENTAL
Intervention: Greater maternal prenatal cortisol reactivity in response to couple conflict discussion
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Greater maternal prenatal cortisol reactivity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Maternal prenatal depressive symptoms
Number of subjects: 123
Study: 31058782

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (AB+)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Healthy controls (AB-)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Additional antibiotic courses
Number of subjects: 436
Study: 31058975

Group type: EXPERIMENTAL
Intervention: Endoscopic ablation of pancreatic neuroendocrine neoplasms
Number of subjects: 0
Study: 31059728

Group type: EXPERIMENTAL
Intervention: Aquablation procedure
Number of subjects: 101
Study: 31060047

Group type: EXPERIMENTAL
Intervention: PFO group (43 patients)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Non-PFO group (273 patients)
Number of subjects: 361
Study: 31060535

Group type: EXPERIMENTAL
Intervention: Body weight, body composition and energy balance related behaviours (EBRB) assessment at four occasions (12 weeks of pregnancy, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary intake, physical activity, sedentary behaviour, smoking habits, sleeping pattern, fatigue, diet and exercise related partner support, mental health, breastfeeding, contraception use, and socio-demographics assessed via questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometry for objective assessment of physical activity and sedentary behaviour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from women's medical records including pre-pregnancy weight and pregnancy outcomes
Number of subjects: 0
Study: 31060562

Group type: EXPERIMENTAL
Intervention: Omega-3 intake < 1.7 g/day
Number of subjects: 421
Study: 31060567

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine (2-dose vaccination schedule)
Number of subjects: 50
Study: 31060612

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (C + P) chemotherapy followed by HPV16-E7 synthetic long peptide (E7LP) vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tri-therapy: C + P chemotherapy, E7LP vaccination, and intravaginal CpG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nanoparticle-conjugated E7LP vaccine
Number of subjects: 0
Study: 31061018

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs)
Number of subjects: 154289

Group type: EXPERIMENTAL
Intervention: Fruit juice
Number of subjects: 154289

Group type: COMPARATOR
Intervention: Fruit intake
Number of subjects: 154289
Study: 31061035

Group type: EXPERIMENTAL
Intervention: Frequent binge drinking between the age of 18 and 25 years (defined as more than twice a month)
Number of subjects: 166

Group type: COMPARATOR
Intervention: No binge drinking (control group)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Frequent binge drinking between the age of 18 and 25 years
Number of subjects: 166
Study: 31061058

Group type: EXPERIMENTAL
Intervention: Care according to national and international guidelines during hospitalisation and follow-up for 6 months after discharge.
Number of subjects: 0
Study: 31061063

Group type: EXPERIMENTAL
Intervention: WYZ mobile health application
Number of subjects: 76
Study: 31061061

Group type: EXPERIMENTAL
Intervention: Blood type A/AB
Number of subjects: 3417

Group type: COMPARATOR
Intervention: Blood type B/O
Number of subjects: 3417
Study: 31061070

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monotherapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intratumoral IL17-mediated signaling
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of drugs targeting the IL17 signaling pathway with T-cell checkpoint inhibitors
Number of subjects: 19
Study: 31061107

Group type: EXPERIMENTAL
Intervention: Frail patients (assessed using the FRAIL Scale)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Intrusive preoperative pain
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Spine surgery
Number of subjects: 116
Study: 31061425

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31061681

Group type: EXPERIMENTAL
Intervention: Urinary TIMP2∗IGFBP7 concentration > 2.0 (ng/ml)
Number of subjects: 112
Study: 31061783

Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External sources
Number of subjects: 0
Study: 31061876

Group type: EXPERIMENTAL
Intervention: Xlimus sirolimus-eluting stent (SES)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Synergy everolimus-eluting stent (EES)
Number of subjects: 180
Study: 31062066

Group type: EXPERIMENTAL
Intervention: Palliative Prostate Artery Embolization (PAE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 15
Study: 31062234

Group type: EXPERIMENTAL
Intervention: oCRH administration
Number of subjects: 27
Study: 31062633

Group type: EXPERIMENTAL
Intervention: Grape/pomegranate pomace dietary supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31062760

Group type: EXPERIMENTAL
Intervention: Women with HFpEF
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1065
Study: 31063537

Group type: EXPERIMENTAL
Intervention: cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor
Number of subjects: 141
Study: 31063862

Group type: EXPERIMENTAL
Intervention: Durvalumab, 1500 mg every 4 weeks, and Olaparib, 300 mg twice a day
Number of subjects: 20
Study: 31064390

Group type: EXPERIMENTAL
Intervention: Implementation facilitation (IF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard educational dissemination strategy
Number of subjects: 120
Study: 31064595

Group type: EXPERIMENTAL
Intervention: Bifactor latent variable approach for measuring irritability and anxiety
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Parent-reported irritability and anxiety factors
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: General negative affectivity factor
Number of subjects: 331
Study: 31064750

Group type: EXPERIMENTAL
Intervention: White patients with HVLPD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonwhite patients with HVLPD
Number of subjects: 16
Study: 31064781

Group type: EXPERIMENTAL
Intervention: BAY 2287411 (mesothelin-targeted thorium-227 conjugate)
Number of subjects: 0
Study: 31064851

Group type: EXPERIMENTAL
Intervention: SY-1365, a selective CDK7 inhibitor
Number of subjects: 0
Study: 31065301

Group type: EXPERIMENTAL
Intervention: Probiotics added to antimicrobial treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31065384

Group type: EXPERIMENTAL
Intervention: C-MAC PM® with Macintosh Blade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-MAC PM® with D-Blade®
Number of subjects: 0
Study: 31065624

Group type: EXPERIMENTAL
Intervention: Molecularly tailored therapy
Number of subjects: 0
Study: 31065773

Group type: EXPERIMENTAL
Intervention: Subxiphoid uniportal VATS lobectomy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional three-port VATS lobectomy
Number of subjects: 105
Study: 31065845

Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (MedDiet)
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: High intake of vegetables, fruits, and nuts; low intake of sugar-sweetened soft beverages
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Nuts consumption
Number of subjects: 2646
Study: 31066021

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 798
Study: 31066678

Group type: EXPERIMENTAL
Intervention: Pep-Pal intervention
Number of subjects: 26
Study: 31066709

Group type: EXPERIMENTAL
Intervention: WHOQOL-Bref questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-12 questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iMTA Productivity Cost Questionnaire (iPCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iMTA Medical Consumption Questionnaire (iMCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study: 31066873

Group type: EXPERIMENTAL
Intervention: Ischemic cardiomyopathy (ICM)
Number of subjects: 11738

Group type: COMPARATOR
Intervention: Nonischemic cardiomyopathy (NICM)
Number of subjects: 11738
Study: 31066879

Group type: EXPERIMENTAL
Intervention: Implementation of prehospital TBI guidelines emphasizing avoidance/treatment of hypoxia, prevention/correction of hyperventilation, and avoidance/treatment of hypotension
Number of subjects: 21852

Group type: EXPERIMENTAL
Intervention: Implementation of prehospital TBI guidelines
Number of subjects: 21852
Study: 31067015

Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet (KD)
Number of subjects: 17
Study: 31067240

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 50
Study: 31067244

Group type: EXPERIMENTAL
Intervention: Out-of-pocket payments after voluntary health insurance reimbursement
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Out-of-pocket payments
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Kakwani index for out-of-pocket payments
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Concentration curves
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Outpatient health care
Number of subjects: 231
Study: 31067538

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) treatment for 2 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Discontinuation of PPI treatment
Number of subjects: 15
Study: 31067570

Group type: EXPERIMENTAL
Intervention: Donor-derived HCMV-specific cytotoxic T cells (CTLs) as first-line therapy
Number of subjects: 0
Study: 31068222

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m2)
Number of subjects: 65
Study: 31068369

Group type: EXPERIMENTAL
Intervention: STM 434 (0.25 mg/kg every 4 weeks to 8 mg/kg every 2 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: STM 434
Number of subjects: 32
Study: 31068370

Group type: EXPERIMENTAL
Intervention: Altered DNA damage repair (DDR) genes
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Patients with altered DDR genes
Number of subjects: 357
Study: 31068479

Group type: EXPERIMENTAL
Intervention: Ipsilateral nonstenotic carotid plaques
Number of subjects: 777

Group type: COMPARATOR
Intervention: No ipsilateral nonstenotic carotid plaques
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 777
Study: 31069056

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative therapies
Number of subjects: 0
Study: 31069128

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis with plasmin
Number of subjects: 0

Group type: COMPARATOR
Intervention: rtPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31070112

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31070470

Group type: EXPERIMENTAL
Intervention: Circadian system influence on VEF
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Circadian system influence on malondialdehyde adducts
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Circadian system influence on endothelin-1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Circadian system influence on blood pressure
Number of subjects: 21
Study: 31070711

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 8 weeks followed by 4 weeks of refeeding
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ketosis (measured by plasma concentration of β-hydroxybutyrate)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 95
Study: 31070733

Group type: EXPERIMENTAL
Intervention: Serum total iodine (StI)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Serum non-protein-bound iodine (SnbI)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Iodine intake
Number of subjects: 1686
Study: 31071145

Group type: EXPERIMENTAL
Intervention: Data-driven continuous quality improvement interventions (CQI) for optimal prevention of mother-to-child transmission (PMTCT) of HIV
Number of subjects: 1377
Study: 31071684

Group type: EXPERIMENTAL
Intervention: Short-term variation (STV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart rate increase across one interbeat interval of phase rectified averaged signal - acceleration capacity (ACst1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scale 4 multi-scale entropy (MSE4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skewness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lempel Ziv complexity (LZC)
Number of subjects: 0
Study: 31072155

Group type: EXPERIMENTAL
Intervention: AOS speakers
Number of subjects: 24
Study: 31072394

Group type: EXPERIMENTAL
Intervention: Future therapeutic HIV vaccine
Number of subjects: 220
Study: 31072581

Group type: EXPERIMENTAL
Intervention: Extracorporeal Life Support (ECLS)
Number of subjects: 0
Study: 31072582

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31072845

Group type: EXPERIMENTAL
Intervention: NCVC-CS1 (honeycomb microporous covered stent)
Number of subjects: 12
Study: 31072858

Group type: EXPERIMENTAL
Intervention: Surgical training programme for practising obstetrician gynaecologist specialists
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Surgical training programme
Number of subjects: 4
Study: 31073022

Group type: EXPERIMENTAL
Intervention: Bendamustine and Ofatumumab
Number of subjects: 21
Study: 31073119

Group type: EXPERIMENTAL
Intervention: DLPFC transcriptome analysis in schizophrenia
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (206 matched controls)
Number of subjects: 189
Study: 31073292

Group type: EXPERIMENTAL
Intervention: Aerobic exercise as add-on treatment, details on dosage and duration not available
Number of subjects: 0